STOCKWATCH
·
Biotechnology: Biological Products (No Diagnostic Substances)
Corporate GovernanceApr 29, 2026, 04:33 PM

BCAB Amends 10-K for Part III Info; 50-for-1 Share Consolidation

AI Summary

BioAtla, Inc. filed an Amendment No. 1 on Form 10-K/A to its Annual Report for the fiscal year ended December 31, 2025. The amendment primarily includes information required by Part III of Form 10-K, which was previously omitted, covering directors, executive officers, and corporate governance. It also updates the cover page and includes new certifications. Additionally, the company effected a 50-for-1 share consolidation on April 6, 2026, retroactively adjusting all share and per share amounts and equity awards.

Key Highlights

  • Amendment to Original Form 10-K to include Part III information.
  • Deletion of proxy statement incorporation reference from cover page.
  • Update of outstanding shares date on cover page.
  • New certifications filed as Exhibits 31.3 and 31.4.
  • 50-for-1 share consolidation effected on April 6, 2026.
  • All share and per share amounts retroactively adjusted for consolidation.
  • Equity awards and warrants proportionally adjusted.
  • Detailed disclosure on Board of Directors and Executive Officers.
BCAB
Biotechnology: Biological Products (No Diagnostic Substances)
BioAtla, Inc.

Price Impact